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Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150S142number of PIRCHES for potential donors prior to HSCT may
allow reducing complications after HLA-mismatched HSCT
by avoiding donors that can recognize higher numbers of
PIRCHE. The present observations indicate that selection of
HLA-mismatched donors with low numbers of PIRCHES may
lead to 5-year survival probabilities similar to 10/10 matched
unrelated donors. These observations require, however,
conﬁrmation in other cohorts. Moreover, the PIRCHES
concept may also be valuable in other HSCT settings, such as
CB transplantation and HSCTwith a 10/10matched unrelated
donor that is mismatched for HLA-DPB1.Figure 1. Kaplan Meier Curves for DFS and OS196
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Background: Umbilical cord blood (UCB) is increasingly used
as a source of unrelated donor hematopoietic cells. Advan-
tages of UCB include immediate graft availability, higher
likelihood of acceptable match, and reduced likelihood and
severity of graft vs. host disease (GVHD). Incorporation of
Busulfan (Bu) with Fludarabine (Flu) in a reduced intensity
conditioning (RIC) regimen has the potential advantages of
improved disease control and acceptable toxicity.
Patients: Eighteen patients (pts), median age 57 years (yrs)
(range 27-70), median weight 83 kg (range 54-127), Karnof-
sky performance status 80-100%, underwent double unit UCB
transplantation for hematologic malignancies (AML 44%; ALL
22%) between January 2012 and February 2013. Early disease
was seen in 44%, intermediate 12%, and advanced 44%.
Adverse cytogeneticswere present in 39%. CMVseropositivity
was seen in 16/18 (89%) pts. Hematopoietic cell trans-
plantation comorbidity index (HCT-CI) scores were HCT-CI
score 0, 44%; score 1-2, 44%; and score > 3, 12%.
Methods: UCB units were 4-6/6 HLA-A, -B antigen, and DRB1
allele matched to the pt, with median 4.36 x 107 total
nucleated cells(TNC)/kg (range 2.86e6.93) per transplant.
RIC regimen included Bu 0.8 mg/kg IV q6h x 8 doses, Flu 35
mg/m2 IV/day x 5, TBI 300-450cGy total, and ATG 1.5 mg/kg/
day x 3. Cyclosporine and mycophenolate mofetil were given
for GVHD prophylaxis.
Results: Median follow up of surviving pts was 12 months.
Day 180 overall survival (OS) was 72%. One yr OS and non-
relapse mortality (NRM) were 45% and 49%, respectively.
Relapse occurred in 1 pt. Cumulative incidence of myeloid
and platelet engraftment was 83% and 72%,median 20 and 47
days (d), respectively. First chimerism evaluation occurred at
median 21 d, all evaluable patients had 95% donor chime-
rism. At day 100, 79% of evaluable pts had single UCB unit
dominance. Acute GVHD grades II-IV occurred in 39% and
grades III-IV in 6% of patients. Chronic GVHD occurred in 17%
during the follow up period. CMV reactivation occurred in 9/
15 at risk pts, median 41 d post-transplant (range 18-54). A
median of 3 CMV reactivations per pt was observed. Two
died with CMV disease during ﬁrst reactivation, while 2others developed ganciclovir resistance. EBV reactivation
occurred in 5/17 pts, 1 pt developed Post Transplant Lym-
phoproliferative Disorder (PTLD) unresponsive to therapy.
One death was due to disseminated mucor.
Discussion: Flu/Bu based RIC regimen for double unit UCB
transplantation is associated with rapid donor chimerism
and possibly reduced disease relapse. Acute GVHD incidence
was low. Failure to achieve neutrophil and platelet engraft-
ment and high incidence of viral reactivation led to signiﬁ-
cant morbidity and high 1 yr NRM. Deﬁnitive conclusions
based on the data are limited by small patient numbers and
short follow up. Further strategies are needed to improve
immune function after RIC double unit UCB transplant.197
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Table 1
Demographics
Mashed Group Mismatched Group
Total Subgroups
N 168 140 Class 1 mismatch 74
Single DR mismatch 13
Single DQ mismatch 18
>1 mismatches 35
Age (yrs) median (range) 55.3 (19.6-73) 52.1 (22.5-72.1)
Sex: Male (%) 95 (56%) 77 (55%)
Diseases: AML/ALL/other AL 72/18/4 67/17/0
MDS/MPD 38/4 30/6
CML/CLL/Other CL 6/0/1 2/0/0
MM/NHL 15/9 10/4
Other 2 4
Conditioning: Bu/Mel/Flu 102 85
TBI/Thio/Cy or Flu 34/27 28/22
Clo/Mel/Thio 4 5
Other 2 0
GvHD, n
Acute / Late acute (Gr 2-4) 17/13 18/17 Class 1 mismatch 7/12
Single DR mismatch 6/1
Single DQ mismatch 3/1
>1 mismatches 2/3
Class 1 mismatch 1/0
Chronic (limited/Ext) 9/4 4/0 Single DR mismatch 1/0
Single DQ mismatch 1/0
>1 mismatches 1/0
Alive, n (%) 103 (61%) 62 (44%) Class 1 mismatch 35 (47%)
Single DR mismatch 6 (46%)
Single DQ mismatch 12 (66%)
>1 mismatches 9 (26%)
Cause of death, n
Disease 21 24 Class 1 mismatch 13
Single DR mismatch 4
Single DQ mismatch 2
>1 mismatches 5
Graft failure 2 7 Class 1 mismatch 3
Single DR mismatch 0
Single DQ mismatch 0
>1 mismatches 4
GvHD 9 12 Class 1 mismatch 8
Single DR mismatch 2
Single DQ mismatch 0
>1 mismatches 2
Infection 18 24 Class 1 mismatch 10
Single DR mismatch 1
Single DQ mismatch 2
>1 mismatches 11
Toxicity 5 4 Class 1 mismatch 2
Single DR mismatch 0
Single DQ mismatch 0
>1 mismatches 2
Others 11 7 Class 1 mismatch 3
Single DR mismatch 0
Single DQ mismatch 2
>1 mismatches 2
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150 S143Guenther Koehne 2, Miguel-Angel Perales 2, Doris M. Ponce 2,
Craig Sauter 2, Marcel R.M. van den Brink 4, James W. Young 2,
Sergio A. Giralt 2, Richard O’Reilly 5, Ann A. Jakubowski 2,6.
1Medicine, Memorial Sloan Kettering Cancer Center, New York,
NY; 2Department of Medicine, Adult Bone Marrow Transplant
Service, Memorial Sloan-Kettering Cancer Center, New York,
NY; 3Department of Biostatistics and Epidemiology,
Memorial Sloan-Kettering Cancer Center, New York, NY;
4 Department of Medicine, Memorial Sloan-Kettering Cancer
Center, New York, NY; 5 Department of Pediatrics, Bone Marrow
Transplant Service, Memorial Sloan-Kettering Cancer Center,
New York, NY; 6Weill Medical College, Cornell University, New
York, NYBackground: T cell depletion (TCD) of HSC grafts has been
shown to reduce the incidence and severity of graft vs host
disease (GvHD) without increasing relapse in appropriately
selected patients. As an alternative to cord blood (CB) grafts,
it makes transplantation an option for patients who lack a
matched donor. We retrospectively reviewed a 13-year
experience of TCD HSC transplants for patients who received
grafts from mismatched unrelated donors (MMUD) as
treatment for hematologic malignancies.
Methods: Under an IRB approved waiver of authorization,
140 adult patients were identiﬁed who received TCD HLA
MMUD grafts during 2000-2013. All HLA typing was by
molecular methods. TCD of BMwas by soybean agglutination
Table 2
Transplant Outcomes for MMUD vs MUD Grafts
Outcome Group N 1-yr CI 2-yr CI p-
value
MUD 169 0.72 (0.64-0.79) 0.60 (0.51-0.67) -
8/10 Loci 31 0.57 (0.38-0.73) 0.43 (0.25-0.60) 0.04
OS 9/10 Loci 105 0.71 (0.61-0.79) 0.56 (0.45-0.65)
Single DQB1 18 0.78 (0.51-0.91) 0.72 (0.45-0.87) 0.44
Single C 26 0.68 (0.46-0.83) 0.45 (0.25-0.64) 0.07
Single class 1
or DRB1
87 0.70 (0.59-0.79) 0.522 (0.41-0.63) 0.17
MUD 169 0.65 (0.57-0.72) 0.54 (0.45-0.62) -
8/10 Loci 31 0.47 (0.29-0.64) 0.40 (0.23-0.57) 0.04
DFS 9/10 Loci 105 0.65 (0.55-0.74) 0.50 (0.40-0.60)
Single DQB 18 0.78 (0.51-0.91) 0.72 (0 45-0.87) 0.29
Single C 26 0.56 (0.35-0.73) 0.37 (0.18-0.56) 0.14
Single DQB1 87 0.64 (0.53-0.73) 0.47 (0.36-0.58) 0.42
MUD 169 0.09 (0.04-0.14) 0.13 (0.08-0.19) -
8/10 Loci 31 0.07 (0.01-0.19) 0.13 (0.40-0.28) 0.36
aGvHD
(Gr 2-4)
9/10 Loci 105 0.14 (0.08-0.22) 0.21 (0.14-0.30)
Single DQB1 18 0.17 (0.04-0.37) 0.17 (0.04-0.37) 0.21
Single C 26 0 04 (0.00-0.17) 0.23 (0.09-0.41) 0.62
Single class 1
or DRB1
87 0.14 (0.08-0.22) 0.22 (0.14-0.32) 0.21
MUD 169 0.05 (0.02-0.09) 0.10 (0.05-0.16) -
8/10 Loci 31 0.03 (0.00-0.15) 0.03 (0.00-0.15) 0.14
cGvHD 9/10 Loci 105 0.03 (0.01-0.08) 0.03 (0.01-0.08)
Single DQB1 18 0.06 (0.00-0.25) 0.06 (0.00-0.25) 0.67
Single C 26 0.05 (0.00-0.20) 0.05 (0.00-0.20) 0.41
Single class 1
or DRB1
87 0.03 (0.00-0.08) 0.03 (0.00-0.08) 0.06
*As appropriate, logrank or Gray’s test p-value comparing outcomes for
single DQB1, Single C and Single class 1 or DRB1 to MUD transplants.
Similarly, outcomes were compared across 8/10 loci, 9/10 loci and 10/10 loci
MUD transplants.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150S144& sheep RBC rosetting (sRBCr) and for PB by automated
CD34+ selection +/- sRBCr. Conditioning regimens were
ablative and all included ATG. Patients were in remission or
had a low volume of disease. No pharmacologic GvHD pro-
phylaxis was given. For different levels of mismatch, overall
(OS) and disease-free survival (DFS) were compared using
Kaplan-Meier curves and the logrank test. Cumulative inci-
dence functions and Gray’s test compared the incidence of
grade 2-4 aGvHD and cGvHD. Results were compared with
169 TCD HLA matched unrelated donor (MUD) grafts during
the same period.
Results: Table 1 lists demographics. Several subgroups had
limited numbers of patients. Table 2 shows cumulative
incidence (CI) for outcomes, and Figure 1 survival curves to 5
yrs. There was no difference in outcomes for 1 loci MMUD vs.
MUD grafts. There was no statistical difference in outcomes
for a single C vs. any single non C mismatch. Nearly all acute
GVHDwas 2-3, and therewere only 4 limited chronic GVHDs.
OS and DFS were lower for >1 loci MMUD transplants.
Conclusion: These results support the use of TCD MMUD
grafts as alternatives for patients lacking a MUD or ineligible
for a CB graft.198
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Aims:We reported the impact of hemophagocytic syndrome
(HPS) on engraftment failure in cord blood transplantation
(CBT). The aim of this study was to explore pathogenesis
underlying HPS.
Methods: We retrospectively reviewed 351 patients who
underwent single CBT using ﬂudarabine-based regimens
at our institute from January 2002 to July 2011
consecutively.
Results: Median age was 58 years (range, 17-82).Diagnoses
were AML/MDS (n¼209), ALL/ML (n¼103), and others
(n¼36). Tacrolimus plus MMF (TAC+MMF) were used in 196
cases as GVHD prophylaxis, while TAC alone in 155. HPS
developed in 33 patients at a median of 19 days post-CBT.
The cumulative incidence of HPS was 9.4%. Development of
HPS had a negative impact signiﬁcantly on neutrophil
engraftment (33.3% with HPS vs 83.3% without HPS,
p¼<0.01), which resulted in inferior overall survival rate.
Majority of the HPS patients (25/30) showed donor-domi-
nant chimerism at the diagnosis of HPS. Patients with severe
form of pre-engraftment immune reactions (sPIR) showed
signiﬁcantly higher incidence of HPS than those without PIR
(51.9% vs 6.6% p¼<0.01). Patients who received cord blood
unit with higher degree of HLA antigen mismatch in GVH
direction (2 vs 0-1) also showed higher incidence of HPS
(11.5% vs 4.8% p¼<0.04). TAC+MMF decreased the incidence
of sPIR and HPS compared to TAC alone (2.8% vs 15.3%
p¼<0.01 and 4.6% vs 15.5% p¼ <0.01, respectively), which
had a trend toward higher engraftment rate (83.7% vs 72.3%
p¼0.07). In multivariate analysis, GVHD prophylaxis using
TAC alone, lower number of CD34+ cells infused (>0.8x105/kg
vs <0.8x105/kg) and higher degree of HLA antigen mismatch
in GVH direction were signiﬁcantly associated with HPS
development.
Conclusion: HPS was closely associated with engraftment
failure in our CBT cohort. sPIR plays an crucial role of
developing HPS and was possibly controlled by intensiﬁca-
tion of GVHD prophylaxis.IMMUNE RECONSTITUTION
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We previously published data from a group of 32 heavily
treated adult cord blood transplant (CBT) recipients and
